Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 24,500 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $7.57, for a total transaction of $185,465.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Clay Thorp also recently made the following trade(s):

  • On Tuesday, August 8th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.98, for a total transaction of $39,900.00.
  • On Monday, August 7th, Clay Thorp sold 4,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.02, for a total transaction of $36,090.00.
  • On Friday, May 19th, Clay Thorp sold 24,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.36, for a total transaction of $200,640.00.
  • On Tuesday, May 16th, Clay Thorp sold 9,544 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.61, for a total transaction of $82,173.84.
  • On Monday, May 15th, Clay Thorp sold 15,941 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.94, for a total transaction of $142,512.54.
  • On Wednesday, May 17th, Clay Thorp sold 44,485 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.63, for a total transaction of $383,905.55.

Clearside Biomedical, Inc. (NASDAQ CLSD) traded down 10.43% during trading on Wednesday, hitting $7.13. 192,888 shares of the stock traded hands. The company’s 50 day moving average price is $9.17 and its 200 day moving average price is $8.06. Clearside Biomedical, Inc. has a 12 month low of $5.44 and a 12 month high of $25.08. The company’s market cap is $180.39 million.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings results on Wednesday, May 10th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.03. The company had revenue of $0.01 million for the quarter. Clearside Biomedical had a negative return on equity of 53.20% and a negative net margin of 154,030.02%. On average, equities research analysts anticipate that Clearside Biomedical, Inc. will post ($1.72) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Sells 24,500 Shares of Stock” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/insider-selling-clearside-biomedical-inc-nasdaqclsd-director-sells-24500-shares-of-stock/1466501.html.

A number of equities analysts have commented on the stock. Cowen and Company reiterated a “buy” rating on shares of Clearside Biomedical in a report on Monday. Zacks Investment Research downgraded shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Monday, July 17th. ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. JMP Securities assumed coverage on shares of Clearside Biomedical in a report on Thursday, May 25th. They issued an “outperform” rating and a $21.00 target price for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $27.00 target price on shares of Clearside Biomedical in a report on Thursday, April 20th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Clearside Biomedical has an average rating of “Buy” and a consensus price target of $19.00.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its position in Clearside Biomedical by 325.0% in the first quarter. Wells Fargo & Company MN now owns 16,739 shares of the company’s stock valued at $133,000 after buying an additional 12,800 shares during the period. State of Wisconsin Investment Board bought a new position in Clearside Biomedical during the second quarter worth about $137,000. TIAA CREF Investment Management LLC raised its position in Clearside Biomedical by 30.7% in the first quarter. TIAA CREF Investment Management LLC now owns 19,257 shares of the company’s stock worth $153,000 after buying an additional 4,527 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Clearside Biomedical during the first quarter worth about $178,000. Finally, Rhumbline Advisers bought a new position in Clearside Biomedical during the second quarter worth about $198,000. 49.67% of the stock is currently owned by institutional investors.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.